Samsung Bioepis-Yuhan Corporation, Domestic Sales Partnership for Autoimmune Disease Treatments

[Asia Economy Reporter Seo So-jung] Samsung Bioepis (CEO Go Han-seung) announced on the 15th that it has signed a marketing partnership with Yuhan Corporation for the domestic sales of the autoimmune disease treatment 'Adaloce'.

Adaloce is a biosimilar of the world's top-selling drug 'Humira' and is the first product to receive sales approval in Korea. It is an autoimmune disease treatment for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, etc., working by inhibiting the expression of tumor necrosis factor (TNF)-alpha in the body.

Since obtaining domestic sales approval for Adaloce in September 2017, Samsung Bioepis has been preparing for its launch through a licensing agreement with the original drug developer AbbVie.

Ahead of the planned launch of Adaloce in the first half of this year, Samsung Bioepis held discussions with multiple companies to select a marketing partner and chose Yuhan Corporation, which has high expertise in the domestic prescription drug market, as the sales company.

With this, Samsung Bioepis will sell biosimilar products for all three blockbuster domestic TNF-alpha inhibitor markets (Humira, Enbrel, Remicade), which are worth approximately 200 billion KRW.

Samsung Bioepis is also conducting domestic sales of its previously launched autoimmune disease treatments 'Etoloce' (Enbrel biosimilar) and 'Remaroce' (Remicade biosimilar) through Yuhan Corporation.

Go Han-seung, CEO of Samsung Bioepis, said, "We are pleased to be able to introduce biosimilar products of the world's most widely used drugs in Korea, and we will continue to strive to expand treatment opportunities for patients through high-quality medicines."

This content was produced with the assistance of AI translation services.